Inhaled fluticasone dipropionate decreases levels of nitric oxide in recurrenty wheezy infants

A. Moeller, Graham Hall, D. Straub, Stephen Stick, Peter Franklin, S.W. Turner, J.H. Wildhaber

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)

Abstract

We examined the effect of inhaled fluticasone diproprionate (FDP) on symptoms, lung function (FEV0.5), and exhaled nitric oxide (Fe-NO) in infants with recurrent wheeze and raised Fe-NO. Thirty-one infants aged 6-19 months (mean, 12.7 months; 12 girls) completed the study. All infants had a history of recurrent wheeze and a parental history of atopy. All children had raised FeNO, as determined by an offline tidal breathing technique prior to randomization. Lung function and Fe-NO were assessed before and after 4 weeks of treatment with FDP or placebo. The parents recorded daily symptoms during the treatment period. Sixteen infants received FDP and 15 the placebo for 4 weeks. At completion of the study, infants treated with FDP had a significant reduction in FeNO (35.0 ppb to 16.5 ppb) compared to those that received placebo (35.2 ppb to 30.2 ppb) (P = 0.05). Small increases in FEV0.5 were observed in both groups, but these changes were not different between groups (P = 0.8). Symptom scores were not significantly different in either group following the intervention. We showed that a moderate dose of inhaled FDP reduces levels of Fe-NO, a potential marker of airway inflammation, even in the absence of significant changes in lung function and symptoms.
Original languageEnglish
Pages (from-to)250-255
JournalPediatric Pulmonology
Volume38
Issue number3
DOIs
Publication statusPublished - 2004

Fingerprint

Dive into the research topics of 'Inhaled fluticasone dipropionate decreases levels of nitric oxide in recurrenty wheezy infants'. Together they form a unique fingerprint.

Cite this